HYLORIS PHARMACEUTICALS SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.7 EUR | -1.27% |
|
-2.50% | -8.24% |
| Mar. 14 | Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024 | CI |
| Mar. 14 | Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024 |
Presenter SpeechJessica McHargue (Executives)Good afternoon, everyone, and thank you for joini...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Hyloris Pharmaceuticals SA is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients and the healthcare system. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives. Hyloris Pharmaceuticals SA currently has two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid analgesic for the treatment of pain. The Company's development strategy primarily focuses on the FDA's 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule has already been established.
Sector
Pharmaceuticals
Calendar
2024-06-03
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.7
EUR
Average target price
21.55
EUR
Spread / Average Target
+84.19%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.24% | 350M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- HYL Stock
- News Hyloris Pharmaceuticals SA
- Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024
